News
Stay up to date on the latest crypto trends with our expert, in-depth coverage.
1SEC crypto safe harbor heads to White House review, proposal due 'shortly' says Atkins2Nvidia CoWoS production capacity to reach 650,000 units in 2026, up 76% year-on-year; 840,000 units in 2027. Next-generation Rubin GPU mass production target lowered from 2 million to 1.5 million units due to HBM4 validation delays.3Geopolitical Pause or Rising Tensions? Markets Brace for Iran's Critical Deadline
Aetna’s Heart Walk Signals Shift to Preventive Care—Could It Drive Lower Claims and Higher Retention?
101 finance·2026/03/27 18:21
Meta's Legal Troubles Cause Shares to Plunge Past Major Averages
101 finance·2026/03/27 18:21
DNA X (SONM) Surges 21.9% on Intraday Spike—What’s Behind the Volatility?
101 finance·2026/03/27 18:18
Alamos Gold Jumps 4.96% Amid Dramatic Intraday Spike: What’s Driving the Surge?
101 finance·2026/03/27 18:15
Cibus Plummets 21.6% in a Shock Intraday Dive – What Just Happened?
101 finance·2026/03/27 18:15
Valero Energy (VLO) Surges to 52-Week High—Is This a Bullish Breakout or Short-Lived Spike?
101 finance·2026/03/27 18:15
Goldman Flags Financials Sector as Epicenter of Institutional Short Bet Amid Fragile Liquidity Setup
101 finance·2026/03/27 18:12
Caris Life Sciences Drops 9.9% – Market Fluctuations and Short-Term Indicators Spark Investor Wariness
101 finance·2026/03/27 18:12
Netskope Drops 9.5% Amid Turbulent Trading as Short-Term Downward Pressure Grows
101 finance·2026/03/27 18:12
Flash
11:33
Climb Bio (stock code: CLYM) announced today that the U.S. Food and Drug Administration (FDA) has granted its candidate drug Budoprutug Fast Track designation for the treatment of primary membranous nephropathy.This designation will accelerate the review process for the drug, offering patients the possibility of earlier access to innovative therapies. Primary membranous nephropathy is an autoimmune kidney disease with limited treatment options. Fast Track designation aims to promote the development and review of drugs for serious diseases where medical needs have not been met. Climb Bio stated it will continue advancing the clinical development plan for Budoprotigide.
11:33
According to the latest revised agreement terms, AC Immune SA will receive a total upfront payment of 10 million Swiss francs.In addition, the company will also receive milestone payments related to the progress of the first phase of the project. This financial arrangement further strengthens the company’s cash flow and provides strong support for subsequent research and development activities.
11:32
Pulse Biosciences (NASDAQ: PLSE) recently announced that its pivotal clinical study of the Npulse™ Cardiac Catheter System for atrial fibrillation treatment (Nanopulse-Af Ide) has completed enrollment of the first group of patients.The study aims to evaluate the safety and efficacy of the system in the treatment of atrial fibrillation, marking a new stage in the company's research and development in this field.
News